Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Lipella Pharmaceuticals Inc. Common Stock
LIPO | US
0.19
USD0.04
25.08%
LIPO | US
About Lipella Pharmaceuticals Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.19
Open
0.20
High
0.20
Low
0.16
Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10 a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310 a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh Pennsylvania.
View LessLIPO | US
Risk
224.2
Sharpe
-0.65
Luna's Score
54/100
Recommendation
Hold
Luna says (LIPO | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
199.9%1 month
224.2%3 months
237.2%6 months
185.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.35
Debt to equity
0.05
Debt to assets
0.04
Ent. to EBITDA
-4.40
Ent. to rev.
6.48
PEG
-
Other Fundamentals
EBITDA
-4.74M
MarketCap
1.57M
MarketCap(USD)
1.57M
Div. yield
-
Op. margin
-697.93
Erngs. growth
-
Rev. growth
27.90
Ret. on equity
-171.56
Short ratio
0.21
Short perc.
3.38
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.04
Range1M
0.09
Range3M
0.18
Volumes: Market Activity
Rel. volume
0.85
Price X volume
814.80
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.40 | 0.53 | Cheaper |
| Ent. to Revenue | 6.48 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.35 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 237.24 | 72.80 | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 1.57M | 3.66B | Emerging |
